TauRx Therapeutics Ltd
Quick facts
Phase 3 pipeline
- TRx0237 · Neurology
TRx0237 is a tau aggregation inhibitor.
Phase 2 pipeline
Phase 1 pipeline
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
Frequently asked questions about TauRx Therapeutics Ltd
What is TauRx Therapeutics Ltd's pipeline?
TauRx Therapeutics Ltd has 1 drugs in Phase 3, 1 in Phase 2, 1 in Phase 1. Late-stage candidates include TRx0237.
Related
- Sector hub: All tracked pharma companies